is a common pathogen that causes foodborne illness worldwide. There is limited evidence describing the treatment of gastrointestinal non-typhoidal (NTS). Clinicians are inclined to treat these infections with antibiotics, but the use of antibiotics may paradoxically worsen gastrointestinal symptoms and prolong bacterial stool shedding. This is a case of gastrointestinal NTS in 30-year-old immunocompetent female patient. She experienced prolonged diarrhea for six weeks following food poisoning with Serovar Enteritidis and received antibiotics as a treatment for her symptoms. The antibiotics worsened her symptoms, and she continued to have positive stool tests. At week 11 following the initial infection, she was advised by her infectious diseases physician to avoid further antibiotic use and take probiotics including and kefir probiotics. These improved her gastrointestinal symptoms; however, she continued to have bacterial stool shedding for a total of 25 weeks. Antibiotics should be avoided for the treatment of gastrointestinal NTS in immunocompetent adults due to their lack of benefit and their potential for worsening and/or prolonging symptoms. Treatment should instead focus on recovering the gut microbiome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742459 | PMC |
| http://dx.doi.org/10.7759/cureus.75953 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Geographical and Socioeconomic Disparities in Substance and Opioid Use Disorders Among Inflammatory Bowel Disease Hospitalizations in the United States From the National Inpatient Sample.
J Clin Psychiatry
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
We compared substance use disorder (SUD) prevalence among adult inflammatory bowel disease (IBD) hospitalizations with non-IBD controls from the 2016-2018 National Inpatient Sample, assessing correlations with demographics, socioeconomic status, geographic regions, depression, and anxiety. The primary aim focused on SUD, defined as substance abuse or dependence (: F10-F19) excluding unspecified use or remission, among hospitalizations documenting IBD (Crohn's disease or ulcerative colitis; : K50-51) as one admitting diagnosis (IBD-D). The prevalence of SUD among hospitalizations with and without IBD was compared.
View Article and Find Full Text PDFA Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.
Cancer Sci
January 2025
Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.
CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. CBA-1205 demonstrates potent antitumor activity in multiple tumor models, making it a potential treatment option for DLK1-expressing cancers.
View Article and Find Full Text PDFAchievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis.
Clin J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 3308777, Japan.
Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs.
View Article and Find Full Text PDFRetrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers.
Cancer Biol Med
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Objective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020.
Methods: CHANNEL was a large, retrospective study using patient-level data from 14 hospitals/cancer centers across China, including adults initiating therapy for newly diagnosed EC (January to December 2018).
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev
January 2025
Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.
Background: Cystic fibrosis is a multisystem disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. Intravenous (IV) antibiotics are commonly used in the treatment of acute deteriorations in symptoms (pulmonary exacerbations); however, recently the assumption that exacerbations are due to increases in bacterial burden has been questioned. This is an update of a previously published review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!